ArticleJournal of the American Heart Association2023
Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2024Pooled it
- Sex Differences in Hypertrophic Cardiomyopathy.Current cardiology reports · 2026Review
- Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data.Journal of the American Heart Association · 2026Observational
- Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2026Article
- Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection.Medical sciences (Basel, Switzerland) · 2026Review
- Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.Future cardiology · 2025Article
- Artificial intelligence electrocardiogram as a novel screening tool to detect and longitudinally monitor high-risk echocardiographic features in hypertrophic cardiomyopathy.Quantitative imaging in medicine and surgery · 2025Article
- Hispanic-Latino Race is Associated with Worse Heart Failure Symptoms in Patients with Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Background Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disease. In small studies, sociodemographic factors have been associated with disparities in septal reduction therapy, but little is known about the association of sociodemographic factors with HCM treatments and outcomes more broadly. Methods and Results Using the National Inpatient Survey from 2012 to 2018, HCM diagnoses and procedures were identified by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.